Literature DB >> 8556523

Epstein-Barr virus-transformed B cells, a potentially convenient source of autologous antigen-presenting cells for the propagation of certain human cytotoxic T lymphocytes.

M B Purner1, R L Berens, E C Krug, T J Curiel.   

Abstract

Antigen-specific cytotoxic T cells (CTL) are generally elicited in vitro by incubation of effector cells with an appropriate major histocompatibility complex-matched antigen-presenting cell (APC). In the case of CTL derived from inbred rodents, spleen cells from an animal of the same strain serve as a ready source of autologous major histocompatibility complex-identical APC. In outbred human populations, however, a convenient source of human leukocyte antigen-matched APC is ordinarily difficult to obtain, and for that reason human antigen-specific CTL may be difficult to propagate. We describe a method whereby Epstein-Barr virus-transformed human B cells (B-LCL) serve as a convenient source of efficient APC for the propagation of human antigen-specific CTL. B-LCL are produced by using B cells from the donor under study and are thus human leukocyte antigen identical to the donor. Using this method, we have propagated human CD4+ Toxoplasma gondii-specific CTL for up to 9 months in vitro, during which time the cells retained their functional capability.

Entities:  

Mesh:

Year:  1994        PMID: 8556523      PMCID: PMC368394          DOI: 10.1128/cdli.1.6.696-700.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  36 in total

1.  Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.

Authors:  R J Orentas; J E Hildreth; E Obah; M Polydefkis; G E Smith; M L Clements; R F Siliciano
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

2.  Differential in vitro activation of CD4+CD8- and CD8+CD4- herpes simplex virus-specific human cytotoxic T cells.

Authors:  M Yasukawa; A Inatsuki; Y Kobayashi
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

3.  Induction and activity of class II-restricted, Lyt-2+ cytolytic T lymphocytes specific for the influenza H5 hemagglutinin.

Authors:  C E Hioe; V S Hinshaw
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

4.  Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.

Authors:  S Koenig; P Earl; D Powell; G Pantaleo; S Merli; B Moss; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  Antigen presentation by EBV-B cells to resting and activated T cells: role of interleukin 1.

Authors:  E T Chu; M Lareau; L J Rosenwasser; C A Dinarello; R S Geha
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

6.  Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens.

Authors:  M J Browning; A S Huang; C S Reiss
Journal:  J Immunol       Date:  1990-08-01       Impact factor: 5.422

7.  Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein.

Authors:  B Culmann; E Gomard; M P Kiény; B Guy; F Dreyfus; A G Saimot; D Sereni; D Sicard; J P Lévy
Journal:  J Immunol       Date:  1991-03-01       Impact factor: 5.422

8.  Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors:  S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal:  Nature       Date:  1990-11-15       Impact factor: 49.962

9.  Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens.

Authors:  M Yasukawa; J M Zarling
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

10.  Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways.

Authors:  S Demotz; P M Matricardi; C Irle; P Panina; A Lanzavecchia; G Corradin
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

View more
  3 in total

1.  Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.

Authors:  Yang Liu; Srilakshmi Pandeswara; Vinh Dao; Álvaro Padrón; Justin M Drerup; Shunhua Lao; Aijie Liu; Vincent Hurez; Tyler J Curiel
Journal:  Cancer Res       Date:  2016-10-13       Impact factor: 12.701

2.  T Cell Receptor Engineered Lymphocytes for Cancer Therapy.

Authors:  Meagan R Rollins; Ellen J Spartz; Ingunn M Stromnes
Journal:  Curr Protoc Immunol       Date:  2020-06

3.  Competition-Based Cell Assay Employing Soluble T Cell Receptors to Assess MHC Class II Antigen Processing and Presentation.

Authors:  Carley Tasker; Jenny Patel; Vibha Jawa; Jad Maamary
Journal:  AAPS J       Date:  2021-01-18       Impact factor: 4.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.